10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Metastatic pheochromocytoma and paraganglioma is disease that has spread to bone, lymph nodes, liver or lungs, the only way these adrenaline-producing tumours are called malignant. It is often slow, so treatment starts with blood pressure control and watching, then moves through radioactive drugs that home to the tumour, the kinase inhibitor sunitinib, chemotherapy and, since 2025, belzutifan.
No pathological feature reliably separates benign from malignant pheochromocytoma and paraganglioma; malignancy is defined by metastases at sites where chromaffin tissue does not normally occur, above all bone, lymph nodes, liver and lung. Metastatic disease occurs in about a tenth of adrenal tumours and a much larger share of extra-adrenal sympathetic paragangliomas, and SDHB mutation, large size, extra-adrenal site and a noradrenergic or dopaminergic profile are the main risk factors. The course is heterogeneous: some patients live for decades with stable bone metastases, others progress within months, so the first decision is whether to treat at all. Catecholamine excess is controlled throughout with alpha-blockade (phenoxybenzamine or doxazosin) and beta-blockade added second, with metyrosine for refractory cases, and any procedure, including biopsy and embolisation, is done under blockade to avoid a hypertensive crisis. Somatostatin receptor PET (68Ga-DOTATATE) and 123I-MIBG scintigraphy stage the disease and, by showing uptake, select patients for the corresponding radionuclide therapy.
Treatment is sequenced by pace. Indolent disease is watched or treated locally with surgery, radiotherapy, ablation or embolisation of dominant lesions. For progressive disease, radionuclide therapy is the first systemic step: high-specific-activity 131I-MIBG (iobenguane, Azedra) was approved in the United States in July 2018 after a single-arm phase 2 trial in which a quarter of 68 patients halved their antihypertensive medication for at least six months and about a fifth had tumour responses, but its production was discontinued and the FDA withdrew the approval at the company's request, because it was no longer marketed, on 8 April 2026; and lutetium-177 dotatate, approved for gastroenteropancreatic neuroendocrine tumours, is used for somatostatin-receptor-positive disease on the strength of retrospective series and phase 2 trials. Sunitinib is the one systemic drug with randomised evidence: FIRSTMAPPP (Lancet 2024), an academic phase 2 trial that took just over seven years (December 2011 to January 2019) to enrol 78 patients, showed 12-month progression-free survival of 36 percent against 19 percent on placebo, meeting its primary endpoint. Cyclophosphamide, vincristine and dacarbazine (CVD) chemotherapy, in use since 1988, and temozolomide, which is active particularly in SDHB-mutant tumours, are the cytotoxic options, and cabozantinib showed activity in the single-arm phase 2 Natalie trial (Lancet Oncology 2024). Belzutifan, the HIF-2 alpha inhibitor, was approved in the United States in May 2025 for adults and children aged 12 and older with locally advanced, unresectable or metastatic disease after a response rate of 26 percent, all partial responses, among 72 patients in the single-arm LITESPARK-015 cohort (New England Journal of Medicine 2025), the first oral drug and the second therapy approved there for the disease; the imipridone ONC206 and radioligand combinations are in trials. Bone metastases, the commonest site, are treated with denosumab or bisphosphonates and palliative radiotherapy.
| Setting | Approach | Guideline |
|---|---|---|
| All patients | Alpha-blockade with beta-blockade added second; metyrosine for refractory symptoms; blockade before every procedure; bone-protective agents for skeletal metastases. | not mapped |
| Staging | 68Ga-DOTATATE PET, 123I-MIBG scintigraphy where 131I-MIBG is available, CT or MRI, FDG-PET for SDHB-related disease; germline testing. | not mapped |
| Indolent disease | Active surveillance; resection, radiotherapy, thermal ablation or embolisation of dominant or symptomatic lesions. | not mapped |
| Progressive disease, radionuclide therapy | Lutetium-177 dotatate for somatostatin-receptor-positive disease; 131I-MIBG for MIBG-avid disease where still available (the high-specific-activity product Azedra was approved in the United States in 2018, its production was discontinued, and the FDA withdrew the approval on 8 April 2026). | not mapped |
| Progressive disease, systemic drugs | Belzutifan (approved 2025); sunitinib (FIRSTMAPPP); cabozantinib; cyclophosphamide, vincristine and dacarbazine or temozolomide for rapidly progressive or SDHB-related disease. | not mapped |
| Trials | ONC206, radioligand combinations and next-generation HIF-2 alpha inhibitors. | not mapped |